Randomized Phase II Study to Assess the Role of Nivolumab as Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients After Chemotherapy (Remain Trial)
This randomized phase II trial studies how well nivolumab works in eliminating any remaining
cancer cells and preventing cancer from returning in patients with acute myeloid leukemia
that had a decrease in or disappearance of signs and symptoms of cancer after receiving
chemotherapy. Monoclonal antibodies, such as nivolumab, may block cancer growth in different
ways by targeting certain cells.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society